SORPTION-LUMINESCENT DETERMINATION OF OROTIC ACID IN MEDICINAL DRUGS

Luminescent properties of orotic acid (vitamin B13), known bioactive substance, have been evaluated in this research. It has been shown that inside a coordination complex of orotic acid with terbium (III) an intermollecular excitation energy transfer from a ligand to a lanthanide ion occurs which causes sensitization of terbium (III) ion luminescence. Intensity of the terbium (III) ion luminescence (ILum) increases in the presence of anionic and cationic surfaceactive agents as a result of displacement of water molecules from coordination sphere of the complex. As a consequence of this process, a non-radiative deactivation of excitation energy decreases and more efficient excitation energy transfer from a ligand to a lanthanide ion occurs. It has been established that after absorption of analyte of interest onto a polymer matrix of a solid phase extraction sorbent with subsequent increasing of its molecular rigidity more efficient excitation energy transfer is observed followed by elevation of luminescence (ILum) intensity of the coordination complex being studied. Intensity of luminescence of coordination complex of orotic acid with terbium (III) in the form of a sorbate salt has been estimated involving different types of sorbents (Phosphalugel, SFG-75, Calflo E, Celite 545, Silicagel Merck). Most suitable results have been achieved by the use of Silica gel Merck as a solid-phase matrix (sorbent). The removal rate of the complex from the solution in this case reaches to 97%. The most effective conditions for determination of orotic acid have been specified. The highest values of luminescence intensity is obtained by conducting of sorption using 5 mL of solution and 100 mg of sorbent. Luminescence intensity of the complex in the form of a sorbate salt, during a sorption process, increases in presence of ethonium, cationic dimeric surface-active agent. Decrease in luminescence intensity of the complexes in the form of a sorbate salt in presence of other surface-active agents may be caused by solubilization of the complex in the solution and thereby reduced level of its sorption. On the basis of presented research work a new analytical procedure has been developed for the solid-phase luminescence determination of orotic acid and orotic acid salts in pharmaceutical drugs. Determination of orotic acid salts has been performed in pharmaceutical drugs ‘Magnerot’ (magnesium orotate) and ‘Potassium orotate’. The proposed analytical procedure for determination of orotic acid salts is remarkable by good metrological characteristics and relative simplicity of performance. The relative standard deviation, Sr, is 3,6 - 4,3%.